WHO Agency UNITAID Features TRU in Tech Landscape Report

NZX/ASX Announcement

3 October 2024

WHO agency UNITAID features TruScreen in its technology landscape report
• UNITAID, a World Health Organisation (WHO) agency featuring health solutions for Low- and Middle-Income countries has included TruScreen in its report “Screening and treatment of pre-cancerous lesions for secondary prevention of cervical cancer”
• TruScreen is the only opto-electrical device included in the technology report
• Report was prepared by UNITAID in collaboration with the Clinton Health Access Initiative (CHAI)
• The report reinforces previous inclusions in national guidelines by,
o the China Obstetrics and Gynaecology Association (COGA) Blue Paper,
o the Chinese Society for Colposcopy and Cervical Pathology (CSCCP)) China Cervical Cancer Screening Management Guideline,
o the Vietnam Ministry of Health National Technical List, and
o COFEPRIS approval for use in Mexico’s public health system.

TruScreen Group Limited (NZX/ASX:TRU) is pleased to announce that our TruScreen Ultra cervical cancer Screening device is included in the UNITAID “Screening and treatment of pre-cancerous lesions for secondary prevention of cervical cancer” technology landscape report.

Full report can be found at: https://unitaid.org/news-blog/unitaid-unveils-new-report-on-technologies-to-prevent-cervical-cancer-a-leading-killer-of-women-worldwide/#en

The report features TruScreen Ultra as the only opto-electrical device recognized in its section on screening by visual assessment or opto-electrical methods and notes the training and validation of the TruScreen algorithm in over 40,000 women in multiple geographical and ethnic settings.

The landscape report was prepared by the Daffodil Centre at the University of Sydney (in partnership with Cancer Council NSW), Australia and the Australian Centre for Prevention of Cervical Cancer (ACPCC) on behalf of UNITAID.

The inclusion in the UNITAID report follows similar inclusions in major national health guidelines
• the China Obstetrics and Gynaecology Association (COGA),
• the Chinese Society for Colposcopy and Cervical Pathology (CSCCP),
• the Vietnam Ministry of Health National Technical List, and
• COFEPRIS, the Mexican public health regulator.

CEO, Mr Martin Dillon commented:
“It is pleasing that TruScreen is included in this global authoritative report, from UNITAID, the Clinton Health Access Initiative, the Daffodil Centre and the Australian Centre for Prevention of Cervical Cancer.




UNITAID’s focus is to close the gap for health access in Low-and-Middle-Income countries. The inclusion in this report aligns with our strategy to focus on countries with poor or no screening capabilities. A Saudi Arabia study concluded that TruScreen “represents a reliable, practical screening tool for cervical neoplasms” and that their results “provide an evidence-based approach for policymakers when selecting the optimal cervical cancer screening strategy in countries without an established national screening program.”

This announcement has been approved by the Board.

Ends



For more information, visit www.truscreen.com or contact:
Martin Dillon
Chief Executive Officer
[email protected]

Guy Robertson
Chief Financial Officer
[email protected]

---

Announcement PDF